Armin Gerger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4257555/publications.pdf

Version: 2024-02-01

131 papers	4,996 citations	101496 36 h-index	102432 66 g-index
133 all docs	133 docs citations	133 times ranked	8441 citing authors

#	Article	IF	Citations
1	Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel. Thrombosis and Haemostasis, 2022, 122, 633-645.	1.8	7
2	Benefit of Metastasectomy in Renal Cell Carcinoma: A Propensity Score Analysis. Clinical Genitourinary Cancer, 2022, 20, 344-353.	0.9	6
3	Evaluation of autoantibodies as predictors of treatment response and immuneâ€related adverse events during the treatment with immune checkpoint inhibitors: AÂprospective longitudinal panâ€cancer study. Cancer Medicine, 2022, 11, 3074-3083.	1.3	16
4	Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study. Frontiers in Immunology, 2022, 13, 840207.	2.2	7
5	Randomized study to investigate a switch maintenance concept with 5-FU plus bevacizumab after FOLFIRI plus cetuximab induction treatment versus continued treatment with FOLFIRI plus cetuximab: Report of a secondary endpoint of the phase-III FIRE-4 study (AIO KRK-0114).. Journal of Clinical Oncology, 2022, 40, 3519-3519.	0.8	5
6	Baseline characteristics of patients enrolled in the BERING CRC study: A European real-world study in BRAF V600E-mutant metastatic colorectal cancer.. Journal of Clinical Oncology, 2022, 40, e15584-e15584.	0.8	0
7	Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. European Journal of Cancer, 2021, 143, 101-112.	1.3	18
8	Decrease in treatment intensity predicts worse outcome in patients with locally advanced head and neck squamous cell carcinoma undergoing radiochemotherapy. Clinical and Translational Oncology, 2021, 23, 543-553.	1.2	2
9	A higher <scp>ctDNA</scp> fraction decreases survival in regorafenibâ€treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase <scp>II</scp> pilot study. International Journal of Cancer, 2021, 148, 1452-1461.	2.3	10
10	Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma. OncoImmunology, 2021, 10, 1896658.	2.1	13
11	The AST/ALT Ratio Is an Independent Prognostic Marker for Disease-free Survival in Stage II and III Colorectal Carcinoma. Anticancer Research, 2021, 41, 429-436.	0.5	11
12	Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110399.	1.4	1
13	Immune Aging and Immunotherapy in Cancer. International Journal of Molecular Sciences, 2021, 22, 7016.	1.8	30
14	T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study. British Journal of Cancer, 2021, 125, 717-724.	2.9	12
15	Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis. European Journal of Cancer, 2021, 151, 3-13.	1.3	29
16	MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms. Cancers, 2021, 13, 3996.	1.7	7
17	Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592098765.	1.4	5
18	Molecular profiling of soft-tissue sarcomas with FoundationOne^{Â®} Heme identifies potential targets for sarcoma therapy: a single-centre experience. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110291.	1.4	3

#	Article	IF	Citations
19	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. Cancers, 2020, 12, 47.	1.7	12
20	Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy. Scientific Reports, 2020, 10, 11219.	1.6	4
21	Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open, 2020, 5, e000872.	2.0	26
22	Diabetes mellitus is independently associated with adverse clinical outcome in soft tissue sarcoma patients. Scientific Reports, 2020, 10, 12438.	1.6	1
23	Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational prospective Phase II study of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients in mCRC. Therapeutic Advances in Medical Oncology, 2020, 12, 1758835920929863.	1.4	12
24	C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study. Cancers, 2020, 12, 2319.	1.7	52
25	Position statement of the Austrian Society for Hematology and Medical Oncology on the use of molecular diagnostics in solid tumors. Memo - Magazine of European Medical Oncology, 2020, 13, 450-452.	0.3	1
26	Molecular profilingâ€"ready for clinical routine. Memo - Magazine of European Medical Oncology, 2020, 13, 365-366.	0.3	0
27	Decreased Activity of Circulating Butyrylcholinesterase in Blood Is an Independent Prognostic Marker in Pancreatic Cancer Patients. Cancers, 2020, 12, 1154.	1.7	9
28	External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients. Cancer Medicine, 2020, 9, 5473-5479.	1.3	15
29	The Lipase/Amylase Ratio (LAR) in Peripheral Blood Might Represent a Novel Prognostic Marker in Patients with Surgically Resectable Pancreatic Cancer. Cancers, 2020, 12, 1798.	1.7	8
30	Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer. Genome Medicine, 2020, 12, 20.	3.6	25
31	The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591990087.	1.4	33
32	Surgery for metachronous metastasis of soft tissue sarcoma â€“ A magnitude of benefit analysis using propensity score methods. European Journal of Surgical Oncology, 2019, 45, 242-248.	0.5	15
33	Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection. Nature Communications, 2019, 10, 4666.	5.8	146
34	Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy. Anticancer Research, 2019, 39, 4589-4596.	0.5	4
35	Critical evaluation of platelet size as a prognostic biomarker in colorectal cancer across multiple treatment settings: a retrospective cohort study. Clinical and Translational Oncology, 2019, 21, 1034-1043.	1.2	3
36	Genetic Analysis Using a Gene Panel in 87 Caucasian Patients With Colorectal Cancer: Own Results and Review of Literature. Anticancer Research, 2019, 39, 847-852.	0.5	3

#	Article	IF	Citations
37	Role of immune checkpoint inhibitors in gastrointestinal cancer treatment. Memo - Magazine of European Medical Oncology, 2019, 12, 71-76.	0.3	2
38	Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Scientific Reports, 2019, 9, 5548.	1.6	19
39	Age as a Predictor of Treatment Outcome in Metastatic Testicular Germ Cell Tumors. Anticancer Research, 2019, 39, 5589-5596.	0.5	8
40	Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer. Clinical Chemistry and Laboratory Medicine, 2019, 57, 740-744.	1.4	8
41	Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. Cancer Medicine, 2018, 7, 508-514.	1.3	13
42	Benefit of Adjuvant Radiotherapy for Local Control, Distant Metastasis, and Survival Outcomes in Patients with Localized Soft Tissue Sarcoma: Comparative Effectiveness Analysis of an Observational Cohort Study. Annals of Surgical Oncology, 2018, 25, 776-783.	0.7	8
43	Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. OncoImmunology, 2018, 7, e1378844.	2.1	179
44	MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. International Journal of Molecular Sciences, 2018, 19, 3130.	1.8	51
45	Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA Surgery, 2018, 153, e180996.	2.2	151
46	Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer. Wiener Klinische Wochenschrift, 2018, 130, 569-574.	1.0	4
47	Leukocyte telomere length throughout the continuum of colorectal carcinogenesis. Oncotarget, 2018, 9, 13582-13592.	0.8	7
48	Can Multistate Modeling of Local Recurrence, Distant Metastasis, and Death Improve the Prediction of Outcome in Patients With Soft Tissue Sarcomas?. Clinical Orthopaedics and Related Research, 2017, 475, 1427-1435.	0.7	29
49	Future perspectives of circulating tumor DNA in colorectal cancer. Tumor Biology, 2017, 39, 101042831770574.	0.8	16
50	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. Clinical Cancer Research, 2017, 23, 5255-5266.	3.2	65
51	Long-term cardiovascular complications in stage I seminoma patients. Clinical and Translational Oncology, 2017, 19, 1400-1408.	1.2	19
52	MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy. Pharmacogenomics, 2017, 18, 1027-1038.	0.6	7
53	My personal highlights of ESMO 2016. Memo - Magazine of European Medical Oncology, 2017, 10, 46-47.	0.3	0
54	Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study. BMC Cancer, 2017, 17, 415.	1.1	13

#	Article	IF	Citations
55	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. Clinical Cancer Research, 2017, 23, 1323-1333.	3.2	67
56	The first meeting of the Austrian Expert Panel for Molecular Cancer Profiling. Memo - Magazine of European Medical Oncology, 2017, 10, 255-258.	0.3	0
57	Risk stratification for venous thromboembolism in patients with testicular germ cell tumors. PLoS ONE, 2017, 12, e0176283.	1.1	39
58	Benefit of second-line chemotherapy for advanced biliary tract cancer.. Journal of Clinical Oncology, 2017, 35, e15621-e15621.	0.8	1
59	Soluble CD87 (s-uPAR) predicts bevacizumab-based first line treatment of metastatic colorectal cancer (mCRC): Results from a prospective multi-center study.. Journal of Clinical Oncology, 2017, 35, 604-604.	0.8	1
60	SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types. PLoS ONE, 2017, 12, e0187814.	1.1	56
61	Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting. Oncotarget, 2017, 8, 96048-96061.	0.8	26
62	Bayesian and frequentist analysis of an Austrian genome-wide association study of colorectal cancer and advanced adenomas. Oncotarget, 2017, 8, 98623-98634.	0.8	23
63	Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients. Anticancer Research, 2017, 37, 2011-2018.	0.5	13
64	The maturation stage of tumoral tertiary lymphoid structures to predict recurrence risk in localized colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15083-e15083.	0.8	0
65	Inflammatory biomarkers as independent predictive and prognostic markers in metastatic colon cancer patients over several treatment lines.. Journal of Clinical Oncology, 2017, 35, e15084-e15084.	0.8	0
66	Clinical characterization of febrile neutropenia episodes in patients with testicular germ cell tumors.. Journal of Clinical Oncology, 2017, 35, e16038-e16038.	0.8	0
67	Current Insights into Long Non-Coding RNAs in Renal Cell Carcinoma. International Journal of Molecular Sciences, 2016, 17, 573.	1.8	66
68	Current Status of Long Non-Coding RNAs in Human Breast Cancer. International Journal of Molecular Sciences, 2016, 17, 1485.	1.8	62
69	Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells. International Journal of Molecular Sciences, 2016, 17, 2011.	1.8	32
70	The width of resection margins influences local recurrence in soft tissue sarcoma patients. European Journal of Surgical Oncology, 2016, 42, 899-906.	0.5	69
71	Potentials, challenges and limitations of a molecular characterization of circulating tumor DNA for the management of cancer patients. Laboratoriums Medizin, 2016, 40, 323-334.	0.1	1
72	Serum sclerostin levels in renal cell carcinoma patients with bone metastases. Scientific Reports, 2016, 6, 33551.	1.6	2

#	Article	IF	Citations
73	Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World Journal of Urology, 2016, 34, 607-611.	1.2	17
74	The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumor Biology, 2016, 37, 361-368.	0.8	39
75	Blood-Based Biomarkers Are Associated with Disease Recurrence and Survival in Gastrointestinal Stroma Tumor Patients after Surgical Resection. PLoS ONE, 2016, 11, e0159448.	1.1	30
76	The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.. Journal of Clinical Oncology, 2016, 34, e15701-e15701.	0.8	0
77	The lymphocyte to monocyte ratio in peripheral blood represents a novel prognostic marker in patients with pancreatic cancer. Clinical Chemistry and Laboratory Medicine, 2015, 53, 499-506.	1.4	68
78	Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. Journal of Clinical Pathology, 2015, 68, 427-433.	1.0	42
79	Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World Journal of Urology, 2015, 33, 1661-1667.	1.2	43
80	LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. Pharmacogenomics Journal, 2015, 15, 391-396.	0.9	11
81	The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients. American Journal of Surgery, 2015, 210, 111-116.	0.9	34
82	Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 201.e9-201.e16.	0.8	25
83	The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. European Journal of Cancer, 2015, 51, 610-619.	1.3	49
84	Genetic markers of recurrence in colorectal cancer. Pharmacogenomics, 2015, 16, 1313-1326.	0.6	13
85	An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients. Breast, 2015, 24, 667-672.	0.9	31
86	The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients. World Journal of Urology, 2015, 33, 1467-1473.	1.2	27
87	Low spinophilin expression enhances aggressive biological behavior of breast cancer. Oncotarget, 2015, 6, 11191-11202.	0.8	10
88	Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. Journal of Clinical Oncology, 2015, 33, 3613-3613.	0.8	0
89	Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. Anticancer Research, 2015, 35, 5737-44.	0.5	61
90	Evaluation of Uric Acid as a Prognostic Blood-Based Marker in a Large Cohort of Pancreatic Cancer Patients. PLoS ONE, 2014, 9, e104730.	1.1	39

#	Article	IF	Citations
91	Pre-Treatment Anemia Is a Poor Prognostic Factor in Soft Tissue Sarcoma Patients. PLoS ONE, 2014, 9, e107297.	1.1	31
92	Germline variants in the SEMA4A gene predispose to familial colorectal cancer type X. Nature Communications, 2014, 5, 5191.	5.8	51
93	Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. British Journal of Cancer, 2014, 110, 183-188.	2.9	154
94	The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. British Journal of Cancer, 2014, 110, 435-440.	2.9	269
95	Current Status of Long Non-Coding RNAs in Human Cancer with Specific Focus on Colorectal Cancer. International Journal of Molecular Sciences, 2014, 15, 13993-14013.	1.8	53
96	Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing. PLoS Genetics, 2014, 10, e1004271.	1.5	157
97	MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. British Journal of Cancer, 2014, 110, 1614-1621.	2.9	109
98	The elevated preoperative platelet to lymphocyte ratio predicts decreased time to recurrence in colon cancer patients. American Journal of Surgery, 2014, 208, 210-214.	0.9	97
99	A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients. Clinical Cancer Research, 2014, 20, 1687-1697.	3.2	20
100	The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. British Journal of Cancer, 2014, 110, 2524-2530.	2.9	232
101	Association of common gene variants in the WNT/Î²-catenin pathway with colon cancer recurrence. Pharmacogenomics Journal, 2014, 14, 142-150.	0.9	28
102	Loss of the putative tumor suppressor protein spinophilin is associated with poor prognosis in head and neck cancer. Human Pathology, 2014, 45, 683-690.	1.1	9
103	The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. Pharmacogenomics Journal, 2014, 14, 130-134.	0.9	16
104	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. Oncotarget, 2014, 5, 8492-8502.	0.8	18
105	MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World Journal of Gastroenterology, 2014, 20, 11727.	1.4	72
106	High preoperative monocyte-lymphocyte ratio (MLR) as a prognostic factor in nonmetastatic clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 534-534.	0.8	2
107	MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Research, 2014, 34, 2709-13.	0.5	36
108	A common gene variant in PLS3 predicts colon cancer recurrence in women. Tumor Biology, 2013, 34, 2183-2188.	0.8	13

#	Article	IF	Citations
109	Association of common gene variants in vitamin D modulating genes and colon cancer recurrence. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1457-1464.	1.2	11
110	Common gene variants in RAD51, XRCC2 and XPD are not associated with clinical outcome in soft-tissue sarcoma patients. Cancer Epidemiology, 2013, 37, 1003-1009.	0.8	10
111	Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. British Journal of Cancer, 2013, 109, 416-421.	2.9	423
112	A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. British Journal of Cancer, 2013, 109, 395-400.	2.9	185
113	External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients. PLoS ONE, 2013, 8, e78225.	1.1	82
114	Validation of the pretreatment neutrophil-lymphocyte ratio as prognostic factor regarding cancer-specific, metastasis-free, and overall survival in a European cohort of patients with renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 410-410.	0.8	2
115	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 393-393.	0.8	1
116	Prediction of clinical outcome in stage II and III colon cancer by a common gene variant in AXIN2.. Journal of Clinical Oncology, 2013, 31, 387-387.	0.8	4
117	liteglinÎ±4 (ITGÎ±4) rs7562325 polymorphism was associated with better survivals in Austrian but not in Japanese patients with gastric cancer.. Journal of Clinical Oncology, 2013, 31, e15009-e15009.	0.8	0
118	Association of transcription factor 7-like 2 (TCF7L2) polymorphisms with worse survival in three independent cohorts from the United States, Austria, and Japan in patients with gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4111-4111.	0.8	0
119	Prognostic outcome of gastric cancer patients with cancer stem cell SNPs in Asian versus western countries.. Journal of Clinical Oncology, 2013, 31, 4110-4110.	0.8	0
120	Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Research, 2013, 33, 4591-4.	0.5	43
121	Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Molecular Genetics and Genomics, 2012, 287, 755-764.	1.0	8
122	MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Research, 2012, 32, 3727-32.	0.5	30
123	Association of interleukin-10 gene variation with breast cancer prognosis. Breast Cancer Research and Treatment, 2010, 119, 701-705.	1.1	42
124	Integrin alpha-2 and beta-3 gene polymorphisms and colorectal cancer risk. International Journal of Colorectal Disease, 2009, 24, 159-163.	1.0	20
125	In vivoconfocal laser scanning microscopy in the diagnosis of melanocytic skin tumours. British Journal of Dermatology, 2009, 160, 475-481.	1.4	72
126	Diagnostic image analysis of malignant melanoma in in vivo confocal laserâ€scanning microscopy: a preliminary study. Skin Research and Technology, 2008, 14, 359-363.	0.8	27

#	Article	IF	Citations
127	In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images. British Journal of Dermatology, 2008, 158, 329-333.	1.4	70
128	A multigenic approach to predict breast cancer risk. Breast Cancer Research and Treatment, 2007, 104, 159-164.	1.1	31
129	Sensitivity and specificity of confocal laser-scanning microscopy for in vivo diagnosis of malignant skin tumors. Cancer, 2006, 107, 193-200.	2.0	178
130	Confocal Examination of Untreated Fresh Specimens From Basal Cell Carcinoma. Archives of Dermatology, 2005, 141, 1269-74.	1.7	28
131	Diagnostic Applicability of In Vivo Confocal Laser Scanning Microscopy in Melanocytic Skin Tumors. Journal of Investigative Dermatology, 2005, 124, 493-498.	0.3	210